Inotropes and vasopressors

Cite this article as:
Anders, M. Inotropes and vasopressors, Don't Forget the Bubbles, 2013. Available at:
http://doi.org/10.31440/DFTB.3876

Definition:

Inotropes: sympathomimetic agent which act on the sympathetic (or adrenergic) nervous system (β-receptors) resulting in positive inotropic (increase in contractility), chronotropic (increase in heart rate), dromotropic (increase in conduction of impulse) and lusitropic effect (improved diastolic relaxation)

Vasopressors: sympathomimetic agent which act on the sympathetic (or noradrenergic) nervous system (α-receptors) resulting in vasoconstrictor effect

The ideal vasoactive support agent: effect on cardiac output/effect on SVR/effect on myocardial oxygen consumption/no tachyphylaxis does not exist!


a) Sympathomimetics: endogenous catecholamines:

Adrenaline (β1 >> β2 and α1 > α2 agonist) via cAMP

Dose

mcg/kg/min

α1α2β1β2Clinical effect
– 0.05++++

↑ HR, SV, CO

(↓) SVR

0.05 – 0.10+++↑ HR, SV, CO
0.10 – 0.20+++++++++

↑ HR, SV, SVR

(↓) CO

Side effects: increasing myocardial oxygen requirement, tachyarrhythmias, worsening diastolic function, tachyphylaxis, hyperglycaemia, lactate increase

Noradrenaline (α1 > α2 and β1 >> β2 agonist) via cAMP ?

Dose

mcg/kg/min

α1α2β1β2Clinical effect
– 0.10++++++++

↑ SVR, HR

(↓) CO

0.10 – 0.20++++++++++

↑ SVR, HR, SV

↓ CO

Side effects: increasing myocardial oxygen requirement, can cause decrease in CO, tachyphylaxis, hyperglycaemia

Dopamine (D1 and D2, higher doses: β1 >> β2 and α1 > α2 agonist) via cAMP. Precursor of norepinephrine

Dose

mcg/kg/min

α1α2β1β2Clinical effect
0.5 – 2↑ increased splanchnic perfusion
2 – 5++↑ HR, SV, CO
5 – 10++++

↑ HR, SV, SVR

(↓) CO

> 10+++

↑ SVR

↓ CO

Side effects: increasing myocardial oxygen requirement, can cause decrease in CO, tachyarrhythmias, tachyphylaxis, hyperglycaemia, immunsuppressive effect, inhibition of thyrotropin releasing hormone

b) Sympathomimetics: synthetic catecholamines:

Dobutamine (β1 >> β2)via cAMP

Dose

mcg/kg/min

α1α2β1β2Clinical effect
2.5 – 10++++

↑ HR, SV, CO

(↓) SVR

> 10+++↑ HR, SV, CO
Side effects: increasing myocardial oxygen requirement, tachyarrhythmias, worsening diastolic function, tachyphylaxis, hyperglycaemia

Isoprenaline (β)via cAMP

Dose

mcg/kg/min

α1α2β1β2Clinical effect
0.01 – 1++++↑ HR, SV, CO
Side effects: increasing myocardial oxygen requirement, tachyarrhythmias, worsening diastolic function, tachyphylaxis, hyperglycaemia

c) Sympathomimetics: synthetic noncatecholamines:

Phenylephrine (α1 >> α2 agonist) – resuscitation in Fallot spells

Dose

mcg/kg/min

α1α2β1β2Clinical effect
0.1 – 5++++++++

↑ SVR

↓ HR (reflex), CO

Side effects: increasing myocardial oxygen requirement,

can cause decrease in CO, tachyphylaxis, hyperglycaemia


d) Phosphodiestarase inhibitors:

Milrinone via cAMP

Dose

mcg/kg/min

Clinical effect
Load: 50mcg/kg
0.2 – 1

↑ CO (positive inotropic and lusitropic effect)

↓ PVR, (SVR)

Side effects: arrhythmia, hypotension (ensure appropriate volume load)

e) Myofilament calcium sensitisers:

Levosimendan via increasing sensitivity to calcium

Dose

mcg/kg/min

Clinical effect

Load: 1.25mcg/kg

over 10min

Infusion: 0.2↑ CO (positive inotropic and lusitropic effect)
Side effects: arrhythmia, hypotension in the first hours

f) Vasoregulatory agents:

Vasopressin (V1 – arterial and V2 – tubular agonist)

Dose

IU/kg/hr

V& V2Clinical effect
0.01 – 0.06+++↑ SVR
Side effects: increasing myocardial oxygen reqirement, can cause decrease in splanchnic perfusion

References:

[1] Am Heart J 2002 Jan; 143(1) : 15-21: Hoffman TM et al: Prophylactic intravenous use of milrinone after cardiac operation in pediatrics (PRIMACORP) study.

[2] Lancet 2002, 306: 196-202: Follath F et al: Efficacy and Safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study); a randomised double-blind trial.

[3] Curr Opin Crit Care. 2010 Oct;16(5):432-41: Parissis et al: Inotropes in cardiac patients: update 2011

[4] Curr Opin Anaesthesiol. 2009 Aug;22(4):496-501: Salmenperä et al: Levosimendan in perioperative and critical care patients.

[5] Pediatr Cardiol. 2004 Nov-Dec;25(6):623-46: Barnes et al: The pediatric cardiology pharmacopoeia: 2004 update

[6] Pediatr Crit Care Med. 2006 Sep;7(5):445-8: Namachivayam P et al: Early experience with Levosimendan in children with ventricular dysfunction.

[7] N Engl J Med. 2008 Feb 28;358(9):877-87: Russel et al: Vasopressin versus norepinephrine infusion in patients with septic shock


 All Marc’s PICU cardiology FOAM can be found on PICU Doctor and can be downloaded as a handy app for free on iPhone or AndroidA list of contributors can be seen here.

If you enjoyed this post, why not check out our live conference on 26th August. Find out more about DFTB: Live + Connected

About Marc Anders

AvatarMarc Anders is a paediatric intensivist.

Avatar
Author: Marc Anders Marc Anders is a paediatric intensivist.

Leave a Reply